Bionomics Limited (NASDAQ:BNOX) Short Interest Update

Bionomics Limited (NASDAQ:BNOXGet Free Report) saw a significant increase in short interest during the month of January. As of January 31st, there was short interest totalling 252,300 shares, an increase of 258.4% from the January 15th total of 70,400 shares. Based on an average daily trading volume, of 236,200 shares, the days-to-cover ratio is currently 1.1 days.

Hedge Funds Weigh In On Bionomics

A hedge fund recently bought a new stake in Bionomics stock. Point72 Asset Management L.P. bought a new position in shares of Bionomics Limited (NASDAQ:BNOXFree Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 128,000 shares of the company’s stock, valued at approximately $595,000. Point72 Asset Management L.P. owned about 1.57% of Bionomics at the end of the most recent quarter. 3.21% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reaffirmed a “buy” rating and set a $8.00 price objective on shares of Bionomics in a research note on Thursday, December 7th.

Get Our Latest Analysis on BNOX

Bionomics Stock Performance

BNOX opened at $1.00 on Tuesday. The company has a quick ratio of 4.87, a current ratio of 4.87 and a debt-to-equity ratio of 0.01. The stock’s 50 day moving average price is $1.16 and its 200-day moving average price is $1.82. Bionomics has a one year low of $0.87 and a one year high of $7.71.

Bionomics Company Profile

(Get Free Report)

Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.

Featured Stories

Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with's FREE daily email newsletter.